as may well Mr PurpleX commiserate “ I remain open but sceptical on holding the remainder”, it would be nice to see that, (mine too), scepticism vanquished.
and regardless of what “may have been” the Vaccine R&D/ FDA approval of the CardioCel IP period was one of positive market sentiment, with a equating sp of $170 plus, and a partnership to boot, before that all changed, …. a paradox exists of a sp that reached those heights, and yet with the, seemingly, compelling results of the current IP a sp at under $20.
surely a NASDAQ listing would be a positive catalyst to change the current status quo, and one that would evaporate some of my scepticism towards the inability of the Company to gaining some level of traction in moving forward, in the area of financial governance, and one that would in turn accelerate and finance the R&D, and in turn advance offers for the Company.
delayed NASDAQ listing will do the Company no favours and ensure that rough times will continue to be so
it would be nice to see this settled once and for all, and a sp that reflects this Company ‘has made it’!
imo.
AVR Price at posting:
$17.35 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)